From its all-time high in August 2021 the largest and most important index for the biotech industry also in Europe (NBI) lost around 25%. After a period of excessive capital inflows, money is much harder to come by these days. The answer can only be more creativity in structuring deals.
The 13th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on approx. 188 colored pages, the guide features a report about sustainibility and the biologisation of industrial production. Readers will discover many success stories and current trends in the European biotech industry.
Biovian Oy’s second generation AAV platform will include Remedium Bio Inc.’s lead treatment candidate against Osteoarthritis.
How to stop hard-to-diagnose, treatment-resistant microbial pathogens was discussed by experts from 13 countries at the 7th AMR Conference in Basel.
With assets of €12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.
DSP Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides selected insights on Catalent’s findings from the collaboration.
DSP?Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides selected insights on Catalents findings from the collaboration.
In soccer, such a transfer would raise tempers: A superstar leaves his team because he no longer trusts it to succeed. A warning sign, a headline event, fodder for weeks of debate in the media. Something similar has just happened to the biotech industry, but things remain strangely quiet in the fan block of Germanys top research – whispers at best, just whispers, but no outcry anywhere.
In a world where biotechnology has been enabling products and processes for decades, it’s time to step out from behind the technology and claim the resulting products and their value in our everyday life. It needs higher visibility and recognition of impact, moving beyond its ‘enabling’ brand which forever makes it sound like the benefits are just around the corner, rather than the existing significant economic and industrial impact.
Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.